BMS Subsidiary Cited for Misleading Consumers on Lung Cancer Drug’s Effectiveness

Mirati Therapeutics has been issued an untitled letter by the FDA for making misleading online claims about the efficacy of its non-small cell lung cancer (NSCLC) drug Krazati (adagrasib), violations considered especially egregious by the agency due to the condition’s serious and devastating nature.
Source: Drug Industry Daily